Insmed (NASDAQ:INSM) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS

Insmed (NASDAQ:INSM) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15), Zacks reports. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed updated its FY 2025 guidance to EPS.

Insmed Stock Performance

Shares of INSM traded down $2.55 during trading hours on Friday, hitting $81.06. The company’s stock had a trading volume of 2,722,240 shares, compared to its average volume of 1,686,738. The business has a 50 day simple moving average of $74.29 and a two-hundred day simple moving average of $73.59. Insmed has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a market cap of $14.50 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11.

Insider Buying and Selling

In other news, CEO William Lewis sold 2,978 shares of Insmed stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08. Following the completion of the sale, the chief executive officer now owns 392,589 shares in the company, valued at approximately $24,874,439.04. This trade represents a 0.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 532,207 shares of company stock valued at $41,400,465. Company insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on INSM. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research note on Wednesday. Morgan Stanley boosted their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Wells Fargo & Company lifted their price target on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday. JPMorgan Chase & Co. upped their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Finally, HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Friday. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $91.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.